A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects with Non-Small Cell Lung Cancer

Brief description of study

This study is for patients with non-small cell lung cancer (NSCLC). In Part 1 of the study, we will enroll patients to test the safety of increasing doses of a drug called MYTX-011, which is a c-MET-targeted antibody-drug conjugate (ADC), and find the right dose that has minimal side effects for further studies. A Safety Review Committee (a group of safety experts) will review the data and help us decide on the best dose.

Once we find the best dose, we will move to Part 2 and include different groups of patients with non-small cell lung cancer. Each group will be studied separately to see how effective the drug is for them. We will also explore additional groups based on their previous treatment. Patients in each group will receive the recommended dose from Part 1.


Clinical Study Identifier: s22-01456
Principal Investigator: Elaine Shum.
Other Investigators: Barbara Crump, Samantha VanMaanen, Jonathan B Kahn, Salman Rafi Punekar, Jessica Wang, Carol M Lee, Sally Lau, Gabrielle Fridman, Joshua K Sabari, Marissa Rybstein, David Mendoza, Melissa L Martinez, Vamsidhar Velcheti, Jeffrey G Schneider, Avital Benson, Natalia Cherkassky, Christy Lynn Spalink.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.